

Table S12. Expression of ClnR-dependent genes in the *clnR* mutant complemented with HIS-ClnR.

| Gene | BHIS | | | + LL-37 (0.5 µg/ml) | | |
|----------------------------|------------------------|-----------------------|--|---------------------|-----------------------|---|
| | 630Δerm pMC123 | <i>clnR</i> pMC123 | <i>clnR</i> pMC123 P <i>clnR</i> ::HIS- <i>clnR</i> RAB | 630Δerm pMC123 | <i>clnR</i> pMC123 | <i>clnR</i> pMC123 P <i>clnR</i> ::HIS- <i>clnR</i> RAB |
| <i>clnA</i> (CD630_16180) | 1.0 ± 0.0 ^a | 37.4 ± 6.6 | 69.4 ± 20.3 | 81.6 ± 20.5 | 44.9 ± 8.0 | 236.5 ± 22.7 |
| <i>vanZ1</i> (CD630_12400) | 1.0 ± 0.0 | 17.5 ± 2.4 | 4.1 ± 1.3 | 15.4. ± 2.8 | 21.8 ± 1.8 | 18.6 ± 2.3 |

^aRelative expression levels were determined by qRT-PCR and are normalized to 630Δerm + pMC123 in BHIS as described in methods. Values shown are the mean of 3 biological replicates ± standard error of the mean.

Additional References

1. Dalgaard P, Koutsoumanis K. Comparison of maximum specific growth rates and lag times estimated from absorbance and viable count data by different mathematical models. *J Microbiol Methods* 2001;43:183-96, NIHMS
2. Pope CF, McHugh TD, Gillespie SH. Methods to determine fitness in bacteria. *Methods Mol Biol* 2010;642:113-21, NIHMS
3. Wust J, Hardegger U. Transferable resistance to clindamycin, erythromycin, and tetracycline in *Clostridium difficile*. *Antimicrob Agents Chemother* 1983;23:784-6.PMCID: PMC184818
4. Hussain HA, Roberts AP, Mullany P. Generation of an erythromycin-sensitive derivative of *Clostridium difficile* strain 630 (630Deltaerm) and demonstration that the conjugative transposon Tn916DeltaE enters the genome of this strain at multiple sites. *J Med Microbiol* 2005;54:137-41, NIHMS
5. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. *Genome Biology* 2009;10:R102.PMCID: 2768977
6. Thomas CM, Smith CA. Incompatibility group P plasmids: genetics, evolution, and use in genetic manipulation. *Annu Rev Microbiol* 1987;41:77-101, NIHMS
7. Yanisch-Perron C, Vieira J, Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 1985;33:103-19, NIHMS
8. Ho TD, Ellermeier CD. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function sigma factors in *Clostridium difficile*. *Infect Immun* 2011;79:3229-38.PMCID: 3147581
9. Manganelli R, Provvedi R, Berneri C, Oggioni MR, Pozzi G. Insertion vectors for construction of recombinant conjugative transposons in *Bacillus subtilis* and *Enterococcus faecalis*. *FEMS Microbiol Lett* 1998;168:259-68, NIHMS
10. McBride SM, Sonenshein AL. Identification of a genetic locus responsible for antimicrobial peptide resistance in *Clostridium difficile*. *Infection and Immunity* 2011;79:167-76.PMCID: 3019887
11. Edwards AN, Nawrocki KL, McBride SM. Conserved oligopeptide permeases modulate sporulation initiation in *Clostridium difficile*. *Infect Immun* 2014;82:4276-91.PMCID: 4187847
12. Dineen SS, McBride SM, Sonenshein AL. Integration of metabolism and virulence by *Clostridium difficile* CodY. *J Bacteriol* 2010;192:5350-62.PMCID: 2950512
13. Woods EC, Nawrocki KL, Suárez JM, McBride SM. The *Clostridium difficile* Dlt pathway is controlled by the ECF sigma factor, σV, in response to lysozyme. *Infection and Immunity* 2016;10.1128/iai.00207-16:IAI.00207-16, NIHMS
14. McKee RW, Mangalea MR, Purcell EB, Borchardt EK, Tamayo R. The second messenger cyclic Di-GMP regulates *Clostridium difficile* toxin production by controlling expression of sigD. *J Bacteriol* 2013;195:5174-85.PMCID: 3811590